<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="368501">
  <stage>Registered</stage>
  <submitdate>21/10/2015</submitdate>
  <approvaldate>12/11/2015</approvaldate>
  <actrnumber>ACTRN12615001242516</actrnumber>
  <trial_identification>
    <studytitle>A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal extract, Testofen, for the treatment of Benign Prostatic Hyperplasia (BPH) symptoms in otherwise healthy males.</studytitle>
    <scientifictitle>A prospective, double-blind, randomised, placebo-controlled study to evaluate the efficacy of a complementary medicine formulation,
to treat symptoms of Benign Prostatic Hyperplasia (BPH) in otherwise healthy male adults.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Treatment of Benign Prostatic Hyperplasia (BPH)</healthcondition>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Herbal remedies</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The treatment is an ARTG listed (Aust L 187768) commercially available capsule-form herbal medicine containing 300mg Trigonella foenum-graecum (Fenugreek) seed extract. The daily dose is 2 capsules per day (total 600mg) taken with the evening meal for a period of 3 months. 

Active ingredient: Trigonella foenum-graecum extract 300mg
equivalent to dry seed 9.9g

Excipient ingredients: Maltodextrin

All participants are provided with a bottle of the product (active or placebo) and a daily urinary frequency diary.

The International Prostate Symptom Score (IPSS) QOL questionnaire and the Male Sexual Health Questionnaire (MSHQ) will be administered at Baseline, Week 4, Week 8 and at trial completion (Week 12).

The Pittsburgh Sleep Quality Index will be administered at Baseline and trial completion (Week 12).  

The following blood tests will also be performed to assess the affect of the product on Dihydrotesterone (DHT), Sex Hormone Binding Globulin (SHBG), serum testosterone and Prostate Specific Antigen (PSA) levels. 

Adherence to the intervention will be monitored by drug tablet return.
</interventions>
    <comparator>The placebo is 2 capsules per day with the evening meal of excipient ingredients only.

</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Frequency of day time and night time urination
Day time and night time urination to be recorded at Baseline (Week 1 Day 1) until trial completion (Week 12 Day 7) using a Daily Diary.</outcome>
      <timepoint>Day time and night time urination to be recorded at Baseline (Week 1 Day 1) until trial completion (Week 12 Day 7) using a Daily Diary.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>BPH symptoms
BPH symptoms to be assessed using the International Prostate Symptom Score (IPSS) QOL questionnaire at Baseline, Week 4, Week 8 and trial completion (Week 12).</outcome>
      <timepoint>BPH symptoms to be assessed using the International Prostate Symptom Score (IPSS) QOL questionnaire at Baseline, Week 4, Week 8 and trial completion (Week 12).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Male sexual health related to lower urinary tract symptoms
Male sexual health to be assessed using the Male Sexual Health Questionnaire (MSHQ) at Baseline, Week 4, Week 8, and trial completion (Week 12).</outcome>
      <timepoint>Male sexual health to be assessed using the Male Sexual Health Questionnaire (MSHQ) at Baseline, Week 4, Week 8, and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep quality
Sleep quality to be assessed using the Pittsburgh Sleep Quality Index questionnaire at Baseline and trial completion (Week 12).</outcome>
      <timepoint>Sleep quality to be assessed using the Pittsburgh Sleep Quality Index questionnaire at Baseline and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>DHT</outcome>
      <timepoint>Levels to be assessed via blood test at Baseline and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>SHBG</outcome>
      <timepoint>Levels to be assessed via blood test at Baseline and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum testosterone</outcome>
      <timepoint>Levels to be assessed via blood test at Baseline and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PSA levels</outcome>
      <timepoint>Levels to be assessed via blood test at Baseline and trial completion (Week 12).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Male aged between 45-80 years
* Medically diagnosed with BPH
* Minimum score of 8 in the IPSS
* Capable of providing informed consent
* Able to attend the required clinics

</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>* Known hypersensitivity to herbal drugs/nutritional supplement/ foods
* Have used a drug/natural therapy for BPH or other urological symptoms within the last 30 days?
* Have had urogenital surgery within the last 6 months?
* Have had bladder biopsy and/or cystoscopy and biopsy within the past 30 days?
* Have been diagnosed with chronic persistent local pathology (e.g. interstitial cystitis, bladder stones)? Receiving/ prescribed Coumadin (Warfarin) or other anticoagulation therapy
* Diagnosed genital anatomical deformities, uncontrolled diabetes mellitus, and history of spinal cord injury, uncontrolled psychiatric disorder, and/or abnormal secondary sexual characteristics
* Diagnosed prostatic cancer or benign hypertrophy; if suspected by the investigator, refer for medical assessment
* Current or history of chronic alcohol and/or drug abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The potential participants are screened by the investigator for inclusion in the study. The eligible participants are enrolled by investigator and provided with a "Numbered Container" that is identical to all other containers and contains the same information on the label, except for the number. The investigator is blinded to the product randomized with the
numbered containers labelled prior to delivery to investigational site.  Product allocated as participants are enrolled in sequential order (1-100).</concealment>
    <sequence>Computer randomized software</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>11/01/2016</anticipatedstartdate>
    <actualstartdate>22/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Amanda Rao</primarysponsorname>
    <primarysponsoraddress>Integrated Health Global Pty Ltd 3B/76 Doggett St, Newstead, QLD 4006</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Gencor Pacific</fundingname>
      <fundingaddress>21-E, Elegance Court
Hillgrove Village
Discovery Bay
Hong Kong
</fundingaddress>
      <fundingcountry>Hong Kong</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Suzanne Abraham</sponsorname>
      <sponsoraddress>The University of Sydney 
Medical School
Edward Ford Building (A27)
Fisher Road
University of Sydney NSW 2006
</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a double-blind, randomised, placebo-controlled study to evaluate the effect of a herbal extract. The aim is to investigatge if the formulation treats benign prostatic hyperplasia (BPH) symptoms in otherwise healthy males.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queensland Clinical Trials Network Inc.</ethicname>
      <ethicaddress>Level 3
88 Jephson Street
TOOWONG QLD 4066</ethicaddress>
      <ethicapprovaldate>4/03/2016</ethicapprovaldate>
      <hrec>HREC2015002</hrec>
      <ethicsubmitdate>1/09/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Amanda Rao</name>
      <address>Integrated Health Global Pty Ltd 3B/76 Doggett St, Newstead, QLD 4006</address>
      <phone>+61 414 488 559</phone>
      <fax />
      <email>amanda@rdglobal.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Amanda Rao</name>
      <address>Integrated Health Global Pty Ltd 3B/76 Doggett St, Newstead, QLD 4006</address>
      <phone>+61 414 488 559</phone>
      <fax />
      <email>amanda@rdglobal.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Amanda Rao</name>
      <address>Integrated Health Global Pty Ltd 3B/76 Doggett St, Newstead, QLD 4006</address>
      <phone>+61 414 488 559</phone>
      <fax />
      <email>amanda@rdcglobal.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Michelle Sethi</name>
      <address>Integrated Health Global Pty Ltd 3B/76 Doggett St, Newstead, QLD 4006</address>
      <phone>+61 408 408 248</phone>
      <fax />
      <email>michelle@rdcglobal.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>